Arvinas Holding Company (ARVN) AI Stock Analysis

• Market Cap: $626.25M
• Dividend Yield: N/A
• Average Volume (3M): 1.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 430
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.84
• Shares Outstanding: 73,417,595
• 10 Day Avg. Volume: 2,852,059
• 30 Day Avg. Volume: 1,856,911
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.50
• Enterprise Value/Revenue: -0.84
• Enterprise Value/Gross Profit: -0.84
• Enterprise Value/Ebitda: 2.71
• 1Y Price Target: $20.46
• Price Target Upside: 140.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 16

• Rating: 48 Neutral
• Price Target: $7.50 ▼(-11.97% Downside)

Arvinas Holding Company's overall stock score reflects significant financial challenges, including persistent losses and declining revenue, which weigh heavily on its valuation. While there is some technical strength and positive developments in clinical trials and partnerships, these are offset by financial restructuring and collaboration issues. Investors should be cautious, focusing on the company's ability to improve its financial health and capitalize on its strategic initiatives.

Positive Factors

Strong Pipeline Progress

Advancements in clinical trials, including the KRAS G12D degrader ARV-806, indicate robust R&D capabilities and potential future revenue streams from successful drug candidates.

Partnership with Novartis

The collaboration with Novartis enhances Arvinas's market position and provides significant financial incentives, supporting long-term growth through milestone payments and royalties.

NDA Submission for Vepdeg

The NDA submission for Vepdeg marks a critical milestone, potentially leading to market entry and revenue generation, showcasing Arvinas's innovative drug development capabilities.

Negative Factors

Revenue Decline

The decline in revenue, primarily due to reduced collaboration income, poses a challenge to financial stability and highlights the need for new revenue sources.

Restructuring Costs

High restructuring costs and workforce reduction indicate financial strain and operational challenges, potentially impacting employee morale and productivity.

Pfizer Collaboration Issues

Collaboration issues with Pfizer may hinder strategic initiatives and revenue potential, necessitating renegotiation or new partnerships to sustain growth.

Arvinas Holding Company Business Overview & Revenue Model

Company Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

How the Company Makes Money

Arvinas generates revenue through several key streams, primarily from partnerships and collaborations with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of the drugs developed using Arvinas's technology. Additionally, the company may receive grant funding for specific research initiatives. The success of Arvinas's revenue model heavily relies on the advancement of its therapeutic candidates through clinical trials and into commercialization, as well as the strength and scale of its partnerships in the biopharmaceutical sector.

Arvinas Holding Company Financial Statement Overview

Summary

Arvinas Holding Company faces significant financial challenges, with persistent losses and declining revenue growth. While the company maintains a strong gross profit margin and low leverage, its negative cash flow from operations and inability to generate profits from equity are concerning. The company needs to focus on improving operational efficiency and revenue growth to enhance its financial health.

Income Statement

Arvinas Holding Company shows a high gross profit margin, indicating efficient cost management. However, the company struggles with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is negative in the TTM, suggesting declining sales, which is concerning for future profitability.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating minimal leverage and financial risk. However, the negative return on equity highlights the company's inability to generate profits from shareholders' equity, which is a significant concern.

Cash Flow

Arvinas has a negative operating cash flow, indicating challenges in generating cash from operations. The free cash flow growth is positive, but the high free cash flow to net income ratio suggests reliance on non-operational activities for cash generation, which may not be sustainable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	372.80M	263.40M	78.50M	131.40M	53.60M	25.90M
Gross Profit	371.40M	263.40M	78.50M	131.40M	53.60M	21.80M
EBITDA	-115.70M	-243.60M	-394.80M	-255.00M	-182.40M	-117.60M
Net Income	-72.60M	-198.90M	-367.30M	-282.50M	-191.00M	-119.30M
Balance Sheet
Total Assets	909.30M	1.09B	1.30B	1.27B	1.58B	717.37M
Cash, Cash Equivalents and Short-Term Investments	861.20M	1.04B	1.26B	1.21B	1.50B	688.53M
Total Debt	9.90M	9.70M	3.20M	5.50M	5.00M	4.10M
Total Liabilities	300.00M	529.70M	644.60M	703.90M	799.90M	75.11M
Stockholders Equity	609.30M	561.70M	660.00M	564.90M	781.70M	642.26M
Cash Flow
Free Cash Flow	-399.00M	-261.10M	-350.70M	-280.30M	554.70M	-96.20M
Operating Cash Flow	-396.40M	-259.30M	-347.80M	-273.50M	559.40M	-89.76M
Investing Cash Flow	347.70M	34.70M	203.50M	242.80M	-1.31B	164.25M
Financing Cash Flow	3.30M	7.90M	374.70M	4.70M	278.60M	504.67M

Arvinas Holding Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Positive. The current price of 8.52 is above the 20-day moving average (MA) of 7.90, above the 50-day MA of 7.57, and below the 200-day MA of 10.68, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 77.63 is Negative, neither overbought nor oversold. The STOCH value of 90.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARVN.

Arvinas Holding Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$655.41M	-7.79	―	―	-100.00%	-25.75%
ANAB	50 Neutral	$651.49M	-6.84	296.41%	―	304.17%	29.37%
ARVN	48 Neutral	$626.25M	―	-35.41%	―	―	―
BCAX	48 Neutral	$756.79M	-8.38	―	―	―	―
OLMA	46 Neutral	$654.77M	-5.09	―	―	―	6.82%
MGTX	41 Neutral	$663.69M	-4.04	-5321.11%	―	366.84%	-35.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Arvinas Holding Company Corporate Events

Arvinas and Pfizer’s FDA Nod for Cancer Drug

On August 8, 2025, Arvinas, in collaboration with Pfizer, announced that the FDA accepted their New Drug Application for vepdegestrant, a PROTAC ER degrader, for treating ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. This acceptance, based on the Phase 3 VERITAC-2 trial, marks a significant step forward as vepdegestrant demonstrated improved progression-free survival compared to fulvestrant, potentially offering a new treatment option for patients with limited alternatives after first-line therapy.

The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.